MODL-17. OBESOGENIC DIET INCREASES NF1-OPTIC PATHWAY GLIOMA FORMATION THROUGH EFFECTS ON THE TUMOR CELL OF ORIGIN

Abstract

Abstract Rates of both pediatric low-grade glioma and obesity have been rising in the U.S., and children of obese mothers have increased rates of several tumor types, including brain tumors. Importantly, obesity in the U.S. is largely dietary-driven, given the prevalence of high fat and high sugar (HFHS) diets. High-fat diet exposure can promote proliferation of embryonic neuroglial progenitor cells (NPCs), which animal modeling suggests are potential cells of origin for low-grade glioma. Together, these data suggested that in utero exposure to an obesogenic diet might affect the formation of pediatric brain tumors. Using preclinical models of the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome, in which optic pathway gliomas (Nf1-OPGs) arise from NPCs in the developing third ventricular zone (TVZ), we sought to determine whether maternal obesogenic exposure would increase glioma formation through intrinsic effects on the tumor cell of origin. We demonstrated that progeny from obese dams exposed to HFHS diet during and preceding gestation had increased proliferation and glial differentiation of WT and Nf1-mutant TVZ NPCs. Progeny of non-obese dams exposed to this diet during gestation demonstrate a similar phenotype, suggesting these effects are related to maternal diet rather than weight. Obesogenic diet exposure (Ob) also increased glioma penetrance in two low-penetrance murine models of Nf1-OPG. Moreover, we demonstrated that Ob mice developed earlier tumor onset with elevated Erk activity in a high-penetrance Nf1-OPG model. In contrast, when obesogenic diet was introduced postnatally, only 11% of mice showed accelerated tumor formation. Ob-exposed nerves also displayed elevated levels of activated Stat3, consistent with upregulation of the IL6/Jak/Stat3 pathway with HFHS diet exposure. These findings establish maternal obesogenic diet as a risk for pediatric glioma formation, in part through in utero effects on the tumor cell of origin, and identify the MAPK and IL6/Jak/Stat3 pathways as targets for further investigation.